Try GOLD - Free
FAKE DRUGS - BOOM PUMMELS PHARMA INDUSTRY
BioSpectrum Asia
|BioSpectrum Asia May 2021
Fake pharmaceuticals are continuing to flood into clinics and hospitals across Asia despite monitored regulations in China and India, when suppliers crossing the border to less-regulated countries. Counterfeiters are moving across certain less regulated locations in Southeast Asia to sustain the trade. Pharmaceutical industry is committed and thriving to sustain and secure the legitimate supply chain. Given the complexity of the supply chain, this is an essential, but laborious effort that requires an efficient, multi-faceted strategy. A holistic approach comprising the use of concealed and unconcealed anti-counterfeiting features, a well-regulated, secure supply chain and appropriate laws and penalties to deter and punish counterfeiters is necessary to provide maximum patient protection.
 As the COVID-19 pandemic continues to affect the world and with the global rush in the development and distribution of vaccines, criminal groups and unscrupulous enterprising people have also been active in counterfeiting COVID-19-related health products. The Philippines through the Philippine Center on Transnational Crime, INTERPOL National Central Bureau, Office of the President of The Philippines has received reports that South African authorities have seized hundreds of fake COVID-19 vaccines and Some 400 ampoules containing the fake vaccine were found at a warehouse in Germiston, Gauteng. Further investigation by the INTERPOL revealed the presence of organized crime networks targeting COVID-19 vaccines, both physically and online. Concerned pharmaceutical companies assisted in the identification of fake vials. Criminals have been put behind bars and investigations are continuing.
According to a FDA Advisory No. 20210664 by The Philippines authorities on Public Health Warning on Fake COVID-19 Vaccines, it noted that in February 2021, the World Health Organization (WHO) reported that a falsified COVID-19 vaccine in Mexico identified as “BNT162b2”, manufactured by Pfizer- BioNTech with lot number 783201. The falsified product was supplied and administered to patients outside authorized vaccination programs. The genuine manufacturer of COVID-19 Vaccine BNT162b2 confirmed they did not manufacture the product. Laboratory analysis of the contents of the falsified products is still pending as of today. Falsified COVID-19 vaccines pose a serious risk to global public health and place an additional burden on vulnerable populations and health systems.
This story is from the BioSpectrum Asia May 2021 edition of BioSpectrum Asia.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM BioSpectrum Asia
 BioSpectrum Asia
Waters launches charge detection mass spectrometry technology
US-based Waters Corporation has unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterisation for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology.
1 min
BioSpectrum Asia Nov 2025
 BioSpectrum Asia
Chulalongkorn University launches Thailand's first master's programme in Nurse Anesthesia
The Faculty of Nursing, Chulalongkorn University, has officially launched the \"Master of Nursing Science Programme in Nurse Anesthesia\" - the first of its kind in Thailand.
1 min
BioSpectrum Asia Nov 2025
 BioSpectrum Asia
WHO strengthens coordination for NTD programmes and supply chain delivery
The World Health Organization (WHO), together with health ministries, pharmaceutical donours, implementing partners and technical support platforms, is strengthening coordination for neglected tropical disease (NTD) programmes and supply chain delivery, through three major back-to-back meetings in Geneva.
1 min
BioSpectrum Asia Nov 2025
 BioSpectrum Asia
All-in-one coronavirus vaccines to save millions in future pandemics
A new study reveals that vaccines designed to protect against a wide range of coronaviruses could dramatically reduce deaths and economic disruption and limit the need for lockdowns in the event of another global coronavirus pandemic.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
NTU in Singapore introduces Master of Science course in Chinese Medicine
From 2026, Nanyang Technological University (NTU) in Singapore will start offering a Master of Science in Chinese Medicine to develop highly skilled postgraduates with advanced expertise in both the theoretical foundations and practical applications of Chinese medicine.
1 min
BioSpectrum Asia Nov 2025
 BioSpectrum Asia
ProSpecBio launches Activin-A recombinant protein for brain injury research
Israel-based ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, has announced the launch of its latest product: CHO cell-derived recombinant Activin-A, now available for immediate delivery worldwide.
1 min
BioSpectrum Asia Nov 2025
 BioSpectrum Asia
PAHO publishes guide for designing AI instructions in public health
The Pan American Health Organization (PAHO) has launched a new guide providing practical advice on how to create Artificial Intelligence (AI) prompts that generate reliable, relevant, and culturally appropriate content across diverse contexts.
1 min
BioSpectrum Asia Nov 2025
 BioSpectrum Asia
Prerna launches India's first MicroRNA based blood test for breast cancer screening
Precision RNA Biotech (Prerna), a healthcare startup from Hyderabad, India has announced the launch of Cantel, India's first microRNA-based blood test for breast cancer screening.
1 min
BioSpectrum Asia Nov 2025
 BioSpectrum Asia
Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr
India-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).
1 min
BioSpectrum Asia Nov 2025
 BioSpectrum Asia
Sumitomo, Novo Nordisk to co-promote obesity drug Wegovy in Japan
Sumitomo Pharma and Novo Nordisk Pharma have entered into a co-promotion agreement in Japan for Wegovy Subcutaneous Injection, a once-weekly subcutaneous injection formulation of GLP-1 receptor agonist indicated for the treatment of obesity disease.
1 min
BioSpectrum Asia Nov 2025
Translate
Change font size
